{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T21:04:43Z","timestamp":1775423083424,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000200"],"award-info":[{"award-number":["82000200"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Clinical Medical Research Center for Lymphatic tumor","award":["2021SK4015"],"award-info":[{"award-number":["2021SK4015"]}]},{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["202203045455"],"award-info":[{"award-number":["202203045455"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xisike-Xinda Clinical Oncology Research Foundation","award":["Y-XD202002-0104"],"award-info":[{"award-number":["Y-XD202002-0104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92963-0","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:13:32Z","timestamp":1741850012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["POD24-Based prognostic signature enables personalized risk stratification in mantle cell lymphoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Yizi","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haige","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"92963_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","volume":"34","author":"A Navarro","year":"2020","unstructured":"Navarro, A., Be\u00e0, S., Jares, P. & Campo, E. Molecular pathogenesis of mantle cell lymphoma. Hematol. Oncol. Clin. North. Am. 34, 795\u2013807. https:\/\/doi.org\/10.1016\/j.hoc.2020.05.002 (2020).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"92963_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain, P. & Wang, M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am. J. Hematol. 94, 710\u2013725. https:\/\/doi.org\/10.1002\/ajh.25487 (2019).","journal-title":"Am. J. Hematol."},{"key":"92963_CR3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/jco.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn, I. W. et al. First-Line treatment of patients with indolent Non-Hodgkin lymphoma or Mantle-Cell lymphoma with Bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year Follow-Up study. J. Clin. Oncol. 37, 984\u2013991. https:\/\/doi.org\/10.1200\/jco.18.00605 (2019).","journal-title":"J. Clin. Oncol."},{"key":"92963_CR4","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/jco.20.02287","volume":"38","author":"P Jain","year":"2020","unstructured":"Jain, P., Dreyling, M., Seymour, J. F. & Wang, M. High-Risk mantle cell lymphoma: definition, current challenges, and management. J. Clin. Oncol. 38, 4302\u20134316. https:\/\/doi.org\/10.1200\/jco.20.02287 (2020).","journal-title":"J. Clin. Oncol."},{"key":"92963_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11864-019-0684-8","volume":"20","author":"AG Jain","year":"2019","unstructured":"Jain, A. G., Chang, C. C., Ahmad, S. & Mori, S. Leukemic Non-nodal mantle cell lymphoma: diagnosis and treatment. Curr. Treat. Options Oncol. 20, 85. https:\/\/doi.org\/10.1007\/s11864-019-0684-8 (2019).","journal-title":"Curr. Treat. Options Oncol."},{"key":"92963_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"Nadeu, F. et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 136, 1419\u20131432. https:\/\/doi.org\/10.1182\/blood.2020005289 (2020).","journal-title":"Blood"},{"key":"92963_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-020-00961-8","volume":"13","author":"D Jung","year":"2020","unstructured":"Jung, D., Jain, P., Yao, Y. & Wang, M. Advances in the assessment of minimal residual disease in mantle cell lymphoma. J. Hematol. Oncol. 13, 127. https:\/\/doi.org\/10.1186\/s13045-020-00961-8 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"92963_CR8","doi-asserted-by":"publisher","unstructured":"Roue, G. & Sola, B. Management of drug resistance in mantle cell lymphoma. Cancers (Basel). 12 https:\/\/doi.org\/10.3390\/cancers12061565 (2020).","DOI":"10.3390\/cancers12061565"},{"key":"92963_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster, E. et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111, 558\u2013565 (2008).","journal-title":"Blood"},{"key":"92963_CR10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","volume":"34","author":"E Hoster","year":"2016","unstructured":"Hoster, E. et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-Cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J. Clin. Oncol. 34, 1386\u20131394. https:\/\/doi.org\/10.1200\/JCO.2015.63.8387 (2016).","journal-title":"J. Clin. Oncol."},{"key":"92963_CR11","doi-asserted-by":"publisher","unstructured":"Zhang, L. et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci. Transl. Med. 11 https:\/\/doi.org\/10.1126\/scitranslmed.aau1167 (2019).","DOI":"10.1126\/scitranslmed.aau1167"},{"key":"92963_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/bjh.17045","volume":"192","author":"AA Moccia","year":"2021","unstructured":"Moccia, A. A. et al. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss group for clinical Cancer research (SAKK). Br. J. Haematol. 192, 1031\u20131034. https:\/\/doi.org\/10.1111\/bjh.17045 (2021).","journal-title":"Br. J. Haematol."},{"key":"92963_CR13","doi-asserted-by":"publisher","unstructured":"Eskelund, C. W. et al. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. Hemasphere 5, e510, (2021). https:\/\/doi.org\/10.1097\/HS9.0000000000000510","DOI":"10.1097\/HS9.0000000000000510"},{"key":"92963_CR14","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/cas.13597","volume":"109","author":"M Yamaguchi","year":"2018","unstructured":"Yamaguchi, M. et al. Early disease progression in patients with localized natural killer\/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci. 109, 2056\u20132062. https:\/\/doi.org\/10.1111\/cas.13597 (2018).","journal-title":"Cancer Sci."},{"key":"92963_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bjh.15643","volume":"185","author":"C Visco","year":"2019","unstructured":"Visco, C. et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br. J. Haematol. 185, 940\u2013944. https:\/\/doi.org\/10.1111\/bjh.15643 (2019).","journal-title":"Br. J. Haematol."},{"key":"92963_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","volume":"35","author":"C Visco","year":"2021","unstructured":"Visco, C. et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia 35, 787\u2013795. https:\/\/doi.org\/10.1038\/s41375-020-01013-3 (2021).","journal-title":"Leukemia"},{"key":"92963_CR17","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks, K. Update on mantle cell lymphoma. Blood 132, 1647\u20131656. https:\/\/doi.org\/10.1182\/blood-2018-03-791392 (2018).","journal-title":"Blood"},{"key":"92963_CR18","doi-asserted-by":"publisher","unstructured":"Ladha, A., Zhao, J., Epner, E. M. & Pu, J. J. Mantle cell lymphoma and its management: where are we now? Experimental hematology & oncology 8, 2, (2019). https:\/\/doi.org\/10.1186\/s40164-019-0126-0","DOI":"10.1186\/s40164-019-0126-0"},{"key":"92963_CR19","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood.2020008727","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill, S. et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood 137, 877\u2013887. https:\/\/doi.org\/10.1182\/blood.2020008727 (2021).","journal-title":"Blood"},{"key":"92963_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","volume":"133","author":"D Dobrovolsky","year":"2019","unstructured":"Dobrovolsky, D. et al. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood 133, 952\u2013961. https:\/\/doi.org\/10.1182\/blood-2018-07-862953 (2019).","journal-title":"Blood"},{"key":"92963_CR21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory Mantle-Cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347 (2020).","journal-title":"N. Engl. J. Med."},{"key":"92963_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster, E. et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111, 558\u2013565. https:\/\/doi.org\/10.1182\/blood-2007-06-095331 (2008).","journal-title":"Blood"},{"key":"92963_CR23","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","volume":"32","author":"E Hoster","year":"2014","unstructured":"Hoster, E. et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European Mantle-Cell lymphoma network. J. Clin. Oncol. 32, 1338\u20131346. https:\/\/doi.org\/10.1200\/JCO.2013.52.2466 (2014).","journal-title":"J. Clin. Oncol."},{"key":"92963_CR24","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/annonc\/mdv074","volume":"26","author":"D Chihara","year":"2015","unstructured":"Chihara, D. et al. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Annals Oncology: Official J. Eur. Soc. Med. Oncol. 26, 966\u2013973. https:\/\/doi.org\/10.1093\/annonc\/mdv074 (2015).","journal-title":"Annals Oncology: Official J. Eur. Soc. Med. Oncol."},{"key":"92963_CR25","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O Determann","year":"2008","unstructured":"Determann, O. et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL network and the German low grade lymphoma study group. Blood 111, 2385\u20132387. https:\/\/doi.org\/10.1182\/blood-2007-10-117010 (2008).","journal-title":"Blood"},{"key":"92963_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2018-05-851667","volume":"133","author":"A Mohanty","year":"2019","unstructured":"Mohanty, A. et al. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood 133, 306\u2013318. https:\/\/doi.org\/10.1182\/blood-2018-05-851667 (2019).","journal-title":"Blood"},{"key":"92963_CR27","doi-asserted-by":"publisher","unstructured":"Yoon, D. H. et al. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian lymphoma study group. J. Hematol. Oncol. 13 https:\/\/doi.org\/10.1186\/s13045-020-00855-9 (2020).","DOI":"10.1186\/s13045-020-00855-9"},{"key":"92963_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5045\/br.2014.49.1.15","volume":"49","author":"BW Kang","year":"2014","unstructured":"Kang, B. W. et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the consortium for improving survival of lymphoma. Blood Res. 49, 15\u201321. https:\/\/doi.org\/10.5045\/br.2014.49.1.15 (2014).","journal-title":"Blood Res."},{"key":"92963_CR29","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/jcp.2005.035071","volume":"59","author":"SS Chuang","year":"2006","unstructured":"Chuang, S. S., Huang, W. T., Hsieh, P. P., Tseng, H. H. & Chang, H. M. Striking male predominance of mantle cell lymphoma in Taiwan. J. Clin. Pathol. 59, 780. https:\/\/doi.org\/10.1136\/jcp.2005.035071 (2006).","journal-title":"J. Clin. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92963-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92963-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92963-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:13:40Z","timestamp":1741850020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92963-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92963"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92963-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4895296\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"11 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"According to ethical policies of the Affiliated Tumor Hospital of Xiangya Medical School Ethics Committee, clinical data can be analyzed and used under the precondition of without revealing the identity of patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statements"}}],"article-number":"8687"}}